Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 59.75M | 55.43M | 59.10M | 72.58M | 73.92M | 78.80M |
Gross Profit | 25.70M | 21.87M | 28.78M | 31.14M | 37.56M | 42.57M |
EBITDA | 118.09M | 255.11M | -129.52M | 159.05M | 157.84M | -97.48M |
Net Income | 175.71M | 222.64M | -162.95M | 129.26M | 130.59M | -121.10M |
Balance Sheet | ||||||
Total Assets | 1.40B | 1.53B | 1.29B | 1.44B | 1.32B | 1.16B |
Cash, Cash Equivalents and Short-Term Investments | 870.44M | 994.86M | 95.01M | 123.96M | 135.52M | 150.18M |
Total Debt | 130.18M | 140.94M | 120.41M | 615.58M | 597.67M | 586.23M |
Total Liabilities | 182.93M | 191.55M | 174.58M | 671.28M | 659.53M | 642.36M |
Stockholders Equity | 1.22B | 1.33B | 1.11B | 769.36M | 653.29M | 518.15M |
Cash Flow | ||||||
Free Cash Flow | 1.61M | -7.44M | -4.89M | -3.40M | -11.23M | -953.00K |
Operating Cash Flow | 2.81M | -4.37M | -3.69M | 3.21M | -1.60M | -232.00K |
Investing Cash Flow | 7.06M | -9.38M | 2.04M | -12.50M | -9.63M | -681.00K |
Financing Cash Flow | -6.48M | -1.58M | -6.50M | -2.29M | -1.80M | -1.69M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | HK$298.75M | 1.35 | 23.02% | ― | -6.21% | ― | |
56 Neutral | HK$44.06M | 33.77 | -2.40% | ― | -40.37% | -112.64% | |
51 Neutral | $7.82B | -0.16 | -39.78% | 2.19% | 21.38% | -1.56% | |
48 Neutral | HK$190.18M | ― | -8.71% | ― | 2.54% | 33.33% | |
45 Neutral | HK$179.70M | ― | -26.80% | ― | -6.09% | 66.59% | |
44 Neutral | HK$264.68M | ― | -40.39% | ― | -43.73% | -434.56% | |
36 Underperform | HK$161.78M | ― | -7.42% | ― | 10.93% | -159.62% |
Extrawell Pharmaceutical Holdings Limited has announced the issuance of new shares under a general mandate. The company has entered into three separate subscription agreements with different subscribers, resulting in the conditional agreement to issue a total of 160,000,000 new shares at a price of HK$0.097 per share. This move is expected to slightly dilute the existing share capital but could provide the company with additional capital for its operations. The completion of these subscriptions is contingent upon certain conditions being met, and stakeholders are advised to exercise caution.
Extrawell Pharmaceutical Holdings Limited has announced its upcoming annual general meeting scheduled for August 22, 2025. The meeting will address ordinary business matters such as the adoption of financial statements, re-election of directors, and re-appointment of auditors. Additionally, special business will include resolutions to authorize directors to allot and issue additional shares, with specific limitations on the number of shares. This announcement indicates the company’s ongoing efforts to manage its corporate governance and shareholder relations effectively.
Extrawell Pharmaceutical Holdings Limited has outlined the terms of reference for its Nomination Committee, which is tasked with ensuring the board’s structure, size, and diversity align with the company’s strategic goals. The committee’s responsibilities include assessing board composition, recommending director appointments, and supporting board performance evaluations, all aimed at enhancing corporate governance and strategic alignment.
Extrawell Pharmaceutical Holdings Limited reported its annual results for the year ended March 31, 2025, showing a significant turnaround with a profit of HK$223.5 million compared to a loss in the previous year. The improvement was driven by gains in other income and reduced selling and distribution expenses, despite a decrease in revenue and increased finance costs.
Extrawell Pharmaceutical Holdings Limited has announced a significant financial turnaround, expecting to report a profit between HK$215 million and HK$225 million for the year ended March 31, 2025, compared to a loss in the previous year. This improvement is primarily due to a gain from the fair value change of financial assets, specifically investments in convertible bonds, marking a positive shift in the company’s financial performance.
Extrawell Pharmaceutical Holdings Limited has announced a board meeting scheduled for June 30, 2025, to approve the annual results for the fiscal year ending March 31, 2025. This meeting is crucial as it will determine the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market positioning.